Clean Margins Matter with George Makhoul of Dilon Technologies

Breast cancer is the most commonly occurring cancer in women and the most common cancer overall. Treatment often starts with a surgery known as a lumpectomy to remove the cancer, but in a high % of cases, patients may undergo multiple re-excisions after their procedure in an attempt to obtain clear margins and avoid mastectomy.

In this episode, CEO of Dilon Technologies, George Makhoul, shares how they are helping to significantly reduce the need for re-excision with the use of their MarginProbe. A lumpectomy is a challenging surgical procedure, complicated by two obvious yet conflicting priorities: excise as much tissue as necessary to remove the cancer from the breast, remove as little tissue as possible to achieve the best cosmetic result.

The MarginProbe System is designed to give today’s surgeons a significant new advantage in margin assessment. In a procedure of roughly five minutes, MarginProbe provides real-time, detailed information to help a surgeon decide whether additional tissue should be taken, or whether to complete the lumpectomy procedure and close the incision.

George’s background in marketing gives him a strong edge in the art of communication with stakeholders which shines through as he details the technology’s journey over the past four years. His consummate professionalism in articulating a clear approach and vision, has helped position Dilon as a leader in its field, backed up by some game-changing innovation that can significantly improve the outcomes for patients. With an inspiring mission for creating impact across the globe for women, this discussion will truly leave you informed and inspired.